Richard Saynor
Richard Saynor is the CEO of Sandoz, a prominent generic pharmaceutical company. He has been at the forefront of navigating the challenges posed by changing economic policies, particularly in the U.S. market, where he aims to expand Sandoz's footprint despite recent production closures in the country.
Not in the pool (under ¢1).
Recent news mentions
Richard Saynor is the CEO of Sandoz, a Swiss generics manufacturer concerned about the declining prices of antibiotics due to competition from Chinese producers.
Wie eine Sandoz-Fabrik die Marktmacht der Chinesen spürt
Switzerland· 2026-05-30Richard Saynor is the CEO of Sandoz and discusses the challenges and opportunities in the antibiotic market.
Sandoz sieht sich bei Antibiotika als letzte Bastion gegen Hersteller aus ChinaSwitzerland· 2026-02-25
Richard Saynor is the CEO of Sandoz and highlights the advantages of the Slovenian education system.
Das Herz der Schweizer Generikafirma schlägt in SlowenienSwitzerland· 2026-02-02
Sandoz chief executive officer Richard Saynor said in a call with analysts Aug. 7 that the company plans to launch 'at some point during 2026.'
Indian pharma giant says Health Canada rejected its application to make generic semaglutide
Canada· 2025-10-30
Richard Saynor has been leading Sandoz since 2019 and is involved in discussions about medication pricing in the USA.
«Zölle motivieren nicht zu Investitionen in den USA»Switzerland· 2025-08-08
Richard Saynor is the CEO of Sandoz, projecting a margin of approximately 21% for the current business year.
trotz hoher Bewertung ein Kauf?Switzerland· 2025-07-02
Richard Saynor is the CEO of Sandoz and discussed the company's investment in Slovenia.
Farmacevti krepijo investicije, nova fakulteta še vedno čaka na začetek gradnje
Slovenia· 2025-07-01Richard Saynor is the CEO of Sandoz and discussed the company's challenges at a press conference.
Zölle könnten Generikahersteller teuer zu stehen kommenSwitzerland· 2025-03-06
